Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT0991 in Relapsed/Refractory Acute Myeloid Leukemia
NCT07233018Phase 1Not yet recruiting
- Sponsor
- MEI HENG
- Start
- Nov 2025
- Primary completion
- Jun 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT0991 in acute myeloid leukemia (AML), sponsored by MEI HENG. Primary endpoints: Maximum Tolerated Dose at 28 days, Adverse Events at 12 months and 1 more. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
CT0991
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07233018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07233018.